 |
市场调查报告书
商品编码
1789537
原发性胆汁性胆管炎治疗市场依治疗类型、通路及地区划分Primary Biliary Cholangitis Treatment Market By Treatment Type, By Distribution Channel, By Region |
||||||
价格
简介目录
原发性胆汁性胆管炎治疗市场规模预计在 2025 年为 7.694 亿美元，预计到 2032 年将达到 13.885 亿美元，2025 年至 2032 年的复合年增长率为 8.8%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025年的市场规模 | 7.694亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期：2025-2032年 | 8.80% | 2032年预测 | 13.885亿美元 |
原发性胆汁性胆管炎 (PBC) 是一种慢性自体免疫肝病，会影响肝臟中的小胆管。随着疾病的进展，这些胆管（称为小管）会形成疤痕而受损，导致胆汁无法在肝臟内自由流动，久而久之会导致肝损伤。 PBC 的主要症状包括疲倦、搔痒和黄疸。如果不及时原发性，PBC 最终会导致肝硬化和肝功能衰竭。 PBC 治疗市场由与该疾病的发病机制和进展有关的各种途径的药物组成。虽然熊去氧胆酸 (UDCA) 仍然是一线治疗药物，但许多患者对该药物反应不足或不耐受。二线治疗药物（如奥贝胆酸和纤维酸衍生物）正在兴起，以满足尚未满足的需求。
市场动态
原发性胆汁性胆管炎治疗市场主要受全球 PBC 盛行率上升的驱动。据多方估计，全球 PBC 盛行率为每百万人 40 至 400 例。市场也受到新型二线治疗方法的推出的推动，这些药物比传统治疗方法具有更高的疗效和更好的耐受性。然而，新药成本高和市场对 PBC 认知度低等因素阻碍了它们的发展。具有新作用机制的在研药物的出现为该市场的参与企业带来了机会。高效安全的治疗方法如果获得监管机构的核准，可以满足难治性患者的需求。
本次调查的主要特点
- 本报告对全球原发性胆汁性胆管炎治疗市场进行了详细分析，并以 2024 年为基准年，介绍了预测期 2025-2032 的市场规模（美国、缅甸）和复合年增长率。
- 它还强调了各个领域的潜在收益成长机会，并说明了针对该市场的引人注目的投资提案。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。
- 全球原发性胆汁性胆管炎治疗市场的主要企业已根据以下参数进行了分析，例如公司亮点、产品系列、关键亮点、绩效和策略。
- 本研究涉及的关键公司包括 Intercept Pharmaceuticals, Inc.、Highlight Therapeutics, SL、GSK plc.、Bristol-Myers Squibb and Company、Enanta Pharmaceuticals、NW BIoTherapeutics、Merck & Cor.、Ipsen Pharma、Johnson & Johnson、GENFIT、Ironr. Pharmaceutical Co., Ltd.
- 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、规模扩大、市场扩张和行销策略做出明智的决策。
- 全球原发性胆汁性胆管炎治疗市场报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员将透过全球原发性胆汁性胆管炎治疗市场分析中使用的各种策略矩阵更轻鬆地做出决策。
目录
第一章：调查目标和先决条件
- 调查目的
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
- 一致的机会图（COM）
第三章：市场动态、法规与趋势分析
- 市场动态
- 原发性胆汁性胆管炎盛行率不断上升
- 扩大新药的采用
- 扩大联合治疗的应用
- 影响分析
- 监管情景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购场景
第四章原发性胆汁性胆管炎治疗市场（依治疗类型），2020 年至 2032 年
- 介绍
- 熊去氧胆酸（UDCA）
- 奥贝胆酸（奥卡利夫）
- 其他（贝特类药物（Tricol）等）
第五章原发性胆汁性胆管炎治疗市场（依通路划分）2020-2032 年
- 介绍
- 医院药房
- 零售药局
- 网路药局
第六章原发性胆汁性胆管炎治疗市场（按地区），2020-2032 年
- 介绍
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 印度
- 中国
- 日本
- 澳洲
- 东南亚国协
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第七章 竞争态势
- Intercept Pharmaceuticals, Inc.
- Highlight Therapeutics, SL
- GSK plc.
- Bristol-Myers Squibb and Company
- Enanta Pharmaceuticals
- NW BIoTherapeutics
- Merck & Co Inc.
- Ipsen Pharma
- Johnson & Johnson
- GENFIT
- Ironwood Pharmaceuticals, Inc.
- Novartis AG
- COUR Pharmaceuticals
- Kaken Pharmaceutical Co., Ltd.
第 8 章 章节
- 调查方法
- 关于出版商
简介目录
Product Code: CMI2555
Primary Biliary Cholangitis Treatment Market is estimated to be valued at USD 769.4 Mn in 2025 and is expected to reach USD 1,388.5 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 769.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.80% | 2032 Value Projection: | USD 1,388.5 Mn |
Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease that affects the small bile ducts in the liver. As the disease progresses, it causes scarring and injury to these bile ducts, known as bile ductules, which stops bile from flowing freely within the liver and damaging it over time. Some key symptoms of PBC include fatigue, itching, and jaundice. If left untreated, PBC can eventually result in cirrhosis or liver failure. The primary biliary cholangitis treatment market consists of drugs that target various pathways involved in the pathogenesis and progression of the disease. Ursodeoxycholic acid (UDCA) remains the first-line treatment but many patients do not adequately respond or are intolerant to it. Second-line treatments such as obeticholic acid and fibric acid derivatives are emerging to address the unmet needs.
Market Dynamics
The primary biliary cholangitis treatment market is primarily driven by the rising prevalence of PBC globally. According to various estimates, the global prevalence of PBC ranges between 40 and 400 cases per million. The market is also propelled by the launch of novel second-line treatment options with higher efficacy and better tolerability profiles than conventional therapies. However, the market growth can be restrained by the high costs of newer drugs and lack of awareness about PBC in developing regions. Emergence of pipeline drugs with novel mechanisms of action represents an opportunity for players in this market. Regulatory approval of efficient and safe therapies can help address the needs of refractory patients.
Key Features of the Study
- This report provides an in-depth analysis of the global primary biliary cholangitis treatment market, and provides market size (US Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global primary biliary cholangitis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- The key companies covered as a part of this study include Intercept Pharmaceuticals, Inc., Highlight Therapeutics, S.L., GSK plc., Bristol-Myers Squibb and Company, Enanta Pharmaceuticals, NW Biotherapeutics, Merck & Co Inc., Ipsen Pharma, Johnson & Johnson, GENFIT, Ironwood Pharmaceuticals, Inc., Novartis AG, COUR Pharmaceuticals, and Kaken Pharmaceutical Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global primary biliary cholangitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary biliary cholangitis treatment market.
Market Segmentation
- By Treatment Type
- Ursodeoxycholic Acid (UDCA)
- Obeticholic Acid (Ocaliva)
- Others (Fibrates (Tricor), etc.)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top Companies in the Primary Biliary Cholangitis Treatment Market
- Intercept Pharmaceuticals, Inc.
- Highlight Therapeutics, S.L.
- GSK plc.
- Bristol-Myers Squibb and Company
- Enanta Pharmaceuticals
- NW Biotherapeutics
- Merck & Co Inc.
- Ipsen Pharma
- Johnson & Johnson
- GENFIT
- Ironwood Pharmaceuticals, Inc.
- Novartis AG
- COUR Pharmaceuticals
- Kaken Pharmaceutical Co., Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Primary Billiary Cholangitis Treatment, By Treatment Type
- Market Primary Billiary Cholangitis Treatment, By Distribution Channel
- Market Primary Billiary Cholangitis Treatment, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Prevalence of Primary Biliary Cholangitis
- Growing Adoption of Novel Drugs
- Increasing adoption of Combination Therapy
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Primary Biliary Cholangitis Treatment Market, By Treatment Type, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Ursodeoxycholic Acid (UDCA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Obeticholic Acid (Ocaliva)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Others (Fibrates (Tricor), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
5. Primary Biliary Cholangitis Treatment Market, By Distribution Channel, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
6. Primary Biliary Cholangitis Treatment Market, By Region, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
- India
- China
- Japan
- Australia
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Intercept Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Highlight Therapeutics, S.L.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Enanta Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- NW Biotherapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GENFIT
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ironwood Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- COUR Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kaken Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
8. Section
- Research Methodology
- About us
02-2729-4219
+886-2-2729-4219
原发性硬化性胆管炎市场按药物类别、给药途径、分销管道和地区划分
原发性胆汁性胆管炎治疗市场 - 按药物（熊去氧胆酸、奥贝胆酸）、用途（人类、兽医）、配销通路（医院药房、药房和零售药房、在线药房） - 全球预测（ 2024 - 2032）